$INTI
Inhibitor Therapeutics, Inc.

2015 Q3 Form 10-Q Financial Statement

#000119312515291734 Filed on August 14, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $600.0K $490.0K $590.0K
YoY Change 5.26% 157.89% 195.0%
% of Gross Profit
Research & Development $601.7K $300.3K $310.0K
YoY Change 260.36% -84.44% 1450.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.202M $791.7K $900.0K
YoY Change 62.86% -62.58% 328.57%
Operating Profit -$1.202M -$791.7K
YoY Change 62.86% -62.58%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.200M -$790.0K -$900.0K
YoY Change 62.16% -63.08% 309.09%
Income Tax
% Of Pretax Income
Net Earnings -$1.202M -$791.7K -$900.0K
YoY Change 62.43% -63.02% 309.09%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 245.4M shares 211.4M shares 211.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.240M $1.890M $370.0K
YoY Change 226.32% 600.0%
Cash & Equivalents $1.243M $1.894M $365.2K
Short-Term Investments
Other Short-Term Assets $60.00K $50.00K $97.82K
YoY Change 27.01% 70.7%
Inventory
Prepaid Expenses $97.82K
Receivables
Other Receivables
Total Short-Term Assets $1.300M $1.940M $463.0K
YoY Change 207.22% 545.5% 4431.45%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $250.0K $250.0K $0.00
YoY Change
Total Long-Term Assets $250.0K $250.0K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.300M $1.940M $463.0K
Total Long-Term Assets $250.0K $250.0K $0.00
Total Assets $1.550M $2.190M $463.0K
YoY Change 266.31% 628.69% 4431.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $442.1K $246.5K $325.0K
YoY Change 33.58% -12.03% 13.2%
Accrued Expenses $103.0K $23.00K
YoY Change 415.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $540.4K $412.7K $400.9K
YoY Change 24.91% -9.07% -48.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $540.4K $412.7K $400.9K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $540.4K $412.7K $400.9K
YoY Change 25.68% -8.29% -48.34%
SHAREHOLDERS EQUITY
Retained Earnings -$35.14M -$33.94M -$32.22M
YoY Change 12.18% 10.96% 14.07%
Common Stock $36.15M $35.71M $32.29M
YoY Change 170881.09% 862151.04% 1709007.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.009M $1.777M $62.08K
YoY Change
Total Liabilities & Shareholders Equity $1.550M $2.190M $463.0K
YoY Change 266.31% 628.69% 4431.45%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q4
OPERATING ACTIVITIES
Net Income -$1.202M -$791.7K -$900.0K
YoY Change 62.43% -63.02% 309.09%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$650.0K -$690.0K -$520.0K
YoY Change 71.05% 137.93% 205.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 2.500M 510.0K
YoY Change -100.0% 346.43% 200.0%
NET CHANGE
Cash From Operating Activities -650.0K -690.0K -520.0K
Cash From Investing Activities
Cash From Financing Activities 0.000 2.500M 510.0K
Net Change In Cash -650.0K 1.810M -10.00K
YoY Change -690.91% 570.37%
FREE CASH FLOW
Cash From Operating Activities -$650.0K -$690.0K -$520.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.075
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
245353270 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
271226
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
245353270 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
245353270 shares
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
166221
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
412691
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
24535
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
246470
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33937283
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35689903
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
103000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
1777155
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2189846
CY2015Q2 us-gaap Liabilities
Liabilities
412691
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1893572
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
46274
CY2015Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1400000
CY2015Q2 us-gaap Assets
Assets
2189846
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
1939846
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
217
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
211419937 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
211419937 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
75933
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
400899
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
21142
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
324966
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32222953
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32263890
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
62079
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462978
CY2014Q4 us-gaap Liabilities
Liabilities
400899
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
365161
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
97817
CY2014Q4 us-gaap Assets
Assets
462978
CY2014Q4 us-gaap Assets Current
AssetsCurrent
462978
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-402629
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19760306 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Profit Loss
ProfitLoss
-2337146
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
19291
us-gaap Operating Income Loss
OperatingIncomeLoss
-2302594
us-gaap Revenues
Revenues
0
us-gaap Interest Expense
InterestExpense
34552
us-gaap Operating Expenses
OperatingExpenses
2302594
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1955807
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
271009
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
19282
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
673638
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
400000
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
273638
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
346787
hppi Noncash Interest Expense
NoncashInterestExpense
24666
hppi In Process Research And Development Paid In Stock And Warrants
InProcessResearchAndDevelopmentPaidInStockAndWarrants
1909860
hppi Issuance Of Common Stock For Common Stock Subscription Receivable
IssuanceOfCommonStockForCommonStockSubscriptionReceivable
110000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
219668924 shares
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
dei Trading Symbol
TradingSymbol
HPPI
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P27M
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-971589
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2500000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
839406
us-gaap Profit Loss
ProfitLoss
-1714330
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
198457
us-gaap Operating Income Loss
OperatingIncomeLoss
-1714330
us-gaap Revenues
Revenues
0
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
90000
us-gaap Operating Expenses
OperatingExpenses
1714330
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
613305
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1528411
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
101792
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2500000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2500000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1101025
hppi Issuance Of Common Stock In Payment Of Trade Payable
IssuanceOfCommonStockInPaymentOfTradePayable
90000
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20622065 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Share Based Compensation
ShareBasedCompensation
839406
hppi Warrant Expiry Date
WarrantExpiryDate
2020-05-15
hppi Restricted Shares For Services Issued Period
RestrictedSharesForServicesIssuedPeriod
P5D
CY2014Q2 us-gaap Profit Loss
ProfitLoss
-2140658
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2115664
CY2014Q2 us-gaap Revenues
Revenues
0
CY2014Q2 us-gaap Interest Expense
InterestExpense
24994
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
2115664
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1930482
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
185182
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
227827263 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2015Q2 us-gaap Profit Loss
ProfitLoss
-791656
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-791656
CY2015Q2 us-gaap Revenues
Revenues
0
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
791656
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
300288
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
491368

Files In Submission

Name View Source Status
0001193125-15-291734-index-headers.html Edgar Link pending
0001193125-15-291734-index.html Edgar Link pending
0001193125-15-291734.txt Edgar Link pending
0001193125-15-291734-xbrl.zip Edgar Link pending
d938337d10q.htm Edgar Link pending
d938337dex101.htm Edgar Link pending
d938337dex102.htm Edgar Link pending
d938337dex103.htm Edgar Link pending
d938337dex104.htm Edgar Link pending
d938337dex105.htm Edgar Link pending
d938337dex106.htm Edgar Link pending
d938337dex311.htm Edgar Link pending
d938337dex312.htm Edgar Link pending
d938337dex321.htm Edgar Link pending
d938337dex322.htm Edgar Link pending
d938337dex41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g938337g00h77.jpg Edgar Link pending
g938337g11w21.jpg Edgar Link pending
g938337g71f83.jpg Edgar Link pending
hppi-20150630.xml Edgar Link completed
hppi-20150630.xsd Edgar Link pending
hppi-20150630_cal.xml Edgar Link unprocessable
hppi-20150630_def.xml Edgar Link unprocessable
hppi-20150630_lab.xml Edgar Link unprocessable
hppi-20150630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending